1254367-47-9

Upstream product

• 67-56-1 methanol 
• 1253799-61-9 3-(benzyloxy)-5-chloroisonicotinic acid 
• 13958-93-5 3,5-dichloropyridine-4-carboxylic acid 
• 100-51-6 benzyl alcohol 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1254367-48-0 C₁₅H₁₅NO₃ 

Relevant academic research and scientific papers

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent (s) ; L is -O-, -S-, -SO- or -SO2-; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is -O-, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is -CRa= or -N=; X2 is -CRb= or -N=; X3 is-CRc= or -N=; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

8-AZA TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.